Patents by Inventor Rajat Varma

Rajat Varma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENGINEERED IL-2 Fc FUSION PROTEINS
    Publication number: 20250092108
    Abstract: The present invention provides IL-2-Fc fusion proteins comprising IL-2 variants.
    Type: Application
    Filed: April 5, 2024
    Publication date: March 20, 2025
    Inventors: Matthew Bernett, John Desjarlais, Rajat Varma, Rumana Rashid
  • IL-15/IL-15RA heterodimeric Fc fusion proteins and uses thereof
    Patent number: 12239688
    Abstract: The present invention is directed to novel IL-15/IL-15R? heterodimeric Fc fusion proteins and uses thereof. The IL-15/IL-15R? heterodimeric Fc fusion proteins can be administered to a patient to treat cancer. In some cases, the IL-15/IL-15R? heterodimeric Fc fusion protein is administered in combination with a checkpoint blockage antibody such as a PD-1 antibody.
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: March 4, 2025
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
  • IL-12 heterodimeric Fc-fusion proteins
    Patent number: 12234270
    Abstract: The present invention provides novel IL-12 Fc fusion proteins, methods of making and using the same. The IL-12 Fc fusion proteins are useful for treatment of cancer and can be used in combination with checkpoint blockade.
    Type: Grant
    Filed: April 11, 2022
    Date of Patent: February 25, 2025
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Nargess Hassanzadeh-Kiabi, Rumana Rashid
  • IL-15/IL-15RA HETERODIMERIC FC FUSION PROTEINS AND USES THEREOF
    Publication number: 20250057919
    Abstract: The present invention is directed to novel IL-15/IL-15R? heterodimeric Fc fusion proteins and uses thereof. The IL-15/IL-15R? heterodimeric Fc fusion proteins can be administered to a patient to treat cancer. In some cases, the IL-15/IL-15R? heterodimeric Fc fusion protein is administered in combination with a checkpoint blockage antibody such as a PD-1 antibody.
    Type: Application
    Filed: November 6, 2024
    Publication date: February 20, 2025
    Inventors: Matthew Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
  • Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
    Patent number: 12139525
    Abstract: The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc fusion protein and an antigen binding domain Fc fusion proteins. In some instances, the antigen binding domain binds to CD8, NKG2A, or NKG2D.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: November 12, 2024
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, John Desjarlais, Rajat Varma, Suzanne Schubbert, Juan Diaz
  • PD-1 TARGETED IL-15/IL-15RALPHA FC FUSION PROTEINS WITH IMPROVED PROPERTIES
    Publication number: 20240294593
    Abstract: The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen binding domains. The present invention also relates to nucleic acid molecules, expression vectors, host cells and methods for making such fusion proteins and the use of such fusion proteins in the treatment of cancer.
    Type: Application
    Filed: January 18, 2024
    Publication date: September 5, 2024
    Inventors: John Desjarlais, Matthew Bernett, Michael Hedvat, Rajat Varma, Suzanne Schubbert, Christine Bonzon, Rumana Rashid, Juan Diaz, Patrick Holder, Christine Huang
  • Untargeted and targeted IL-10 Fc-fusion proteins
    Patent number: 12006345
    Abstract: The present invention provides untargeted and targeted IL-10-Fc fusion proteins, compositions and methods of use thereof. The targeted IL-10-Fc fusion proteins includes those that bind PD-1, TIGIT, CD8 and NKG2D.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: June 11, 2024
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Rajat Varma, Yoon Kyung Kim, Rumana Rashid, Alex Nisthal, Juan Diaz, Matthew Bernett, Michael Hedvat
  • Engineered IL-2 Fc fusion proteins
    Patent number: 11981717
    Abstract: The present invention provides IL-2-Fc fusion proteins comprising IL-2 variants.
    Type: Grant
    Filed: January 18, 2022
    Date of Patent: May 14, 2024
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, John Desjarlais, Rajat Varma, Rumana Rashid
  • PD-1 targeted IL-15/IL-15R? Fc fusion proteins with improved properties
    Patent number: 11932675
    Abstract: The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen binding domains. The present invention also relates to nucleic acid molecules, expression vectors, host cells and methods for making such fusion proteins and the use of such fusion proteins in the treatment of cancer.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: March 19, 2024
    Assignees: GENENTECH, INC., XENCOR, INC.
    Inventors: John Desjarlais, Matthew Bernett, Michael Hedvat, Rajat Varma, Suzanne Schubbert, Christine Bonzon, Rumana Rashid, Juan Diaz, Patrick Holder, Christine Huang
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND GPC3
    Publication number: 20240034815
    Abstract: Provided herein are novel GPC3 binding domains, and antibodies that include such GPC3 binding domains (e.g., anti-GPC3×anti-CD3). Also provided herein are methods of using such antibodies for the treatment of GPC3-associated cancers.
    Type: Application
    Filed: July 25, 2023
    Publication date: February 1, 2024
    Inventors: Alex Nisthal, Nargess Hassanzadeh-Kiabi, Katrina Bykova, Matthew J. Bernett, Rajat Varma
  • Heterodimeric antibodies that bind CD3 and GPC3
    Patent number: 11859012
    Abstract: Provided herein are novel GPC3 binding domains, and antibodies that include such GPC3 binding domains (e.g., anti-GPC3×anti-CD3). Also provided herein are methods of using such antibodies for the treatment of GPC3-associated cancers.
    Type: Grant
    Filed: March 10, 2022
    Date of Patent: January 2, 2024
    Assignee: Xencor, Inc.
    Inventors: Alex Nisthal, Nargess Hassanzadeh-Kiabi, Katrina Bykova, Matthew J. Bernett, Rajat Varma
  • Targeted IL-12 heterodimeric Fc-fusion proteins
    Patent number: 11851466
    Abstract: The present invention relates to targeted IL-12 heterodimeric Fc fusion proteins, where the fusion proteins bind to human PD-1 or human PD-L1.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: December 26, 2023
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Rumana Rashid, Nargess Hassanzadeh-Kiabi, Michael Hedvat
  • TARGETED HETERODIMERIC FC FUSION PROTEINS CONTAINING IL-15/IL-15RA AND NKG2D ANTIGEN BINDING DOMAINS
    Publication number: 20230340053
    Abstract: The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL,-15R? Fc fusion protein and an NKG2D antigen binding domain Fc fusion proteins.
    Type: Application
    Filed: October 18, 2022
    Publication date: October 26, 2023
    Inventors: Matthew J. Bernett, John R. Desjarlais, Rajat Varma, Gregory Moore, Juan Diaz, Alex Nisthal, Ke Liu, Rumana Rashid, Eric Chang
  • TIM-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND TIM-3 ANTIGEN BINDING DOMAINS
    Publication number: 20230331813
    Abstract: The present invention is directed to novel targeted heterodimeric fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a TIM-3 antibody fragment-Fc fusion protein.
    Type: Application
    Filed: October 13, 2022
    Publication date: October 19, 2023
    Inventors: Matthew J. Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
  • LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS
    Publication number: 20230279071
    Abstract: The present invention is directed to novel targeted heterodimeric fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a LAG-3 antibody fragment-Fc fusion protein.
    Type: Application
    Filed: April 28, 2023
    Publication date: September 7, 2023
    Inventors: Matthew J. Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
  • BISPECIFIC HETERODIMERIC FUSION PROTEINS CONTAINING IL-15 - IL-15Ralpha Fc-FUSION PROTEINS AND IMMUNE CHECKPOINT ANTIBODY FRAGMENTS
    Publication number: 20230220081
    Abstract: The present invention is directed to novel bispecific heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein.
    Type: Application
    Filed: December 13, 2022
    Publication date: July 13, 2023
    Inventors: Matthew Bernett, Rumana Rashid, John Desjarlais, Rajat Varma, Christine Bonzon
  • IL-12 heterodimeric Fc-fusion proteins
    Patent number: 11655277
    Abstract: The present invention provides novel IL-12 Fc fusion proteins, methods of making and using the same. The IL-12 Fc fusion proteins are useful for treatment of cancer and can be used in combination with checkpoint blockade.
    Type: Grant
    Filed: August 11, 2022
    Date of Patent: May 23, 2023
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Nargess Hassanzadeh-Kiabi, Rumana Rashid
  • Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
    Patent number: 11618776
    Abstract: The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc fusion protein and an NKG2D antigen binding domain Fc fusion proteins.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: April 4, 2023
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, John R. Desjarlais, Rajat Varma, Gregory Moore, Juan Diaz, Alex Nisthal, Ke Liu, Rumana Rashid, Eric Chang
  • PD-1 TARGETED IL-15/IL-15RALPHA FC FUSION PROTEINS AND USES IN COMBINATION THERAPIES THEREOF
    Publication number: 20230055445
    Abstract: The present invention is directed to novel PD-1 targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein. In some embodiments, the PD-1 targeted IL-15/R?-Fc fusion proteins are administered to a patient to treat cancer. In some embodiments, the PD-1 targeted IL-15/R?-Fc fusion proteins are administered in combination with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab. In some embodiments, the PD-1 targeted IL-15/R?-Fc fusion proteins do not compete with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab for antigen binding.
    Type: Application
    Filed: June 2, 2022
    Publication date: February 23, 2023
    Inventors: Matthew Bernett, John R. Desjarlais, Michael Hedvat, Suzanne Schubbert, Christine Bonzon, Rumana Rashid, Rajat Varma
  • Bispecific heterodimeric fusion proteins containing IL-15-IL-15Ralpha Fc-fusion proteins and immune checkpoint antibody fragments
    Patent number: 11584794
    Abstract: The present invention is directed to novel bispecific heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: February 21, 2023
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Rumana Rashid, John Desjarlais, Rajat Varma, Christine Bonzon